High-Precision non-invasive robotic Radiosurgery for Prostate Cancer
Advanced CyberKnife® technology targeting tumors with extreme accuracy. Designed to maximize efficacy while preserving your quality of life.No surgery. No hospital stay.
Within 24 Hours
20+ years of radiosurgery experience
Thousands of patients treated
International reference center
Prof. Dr. med. Alexander Muacevic
Director of the ERCM
A Different Level of Precision
At our international reference center, we focus on one thing: delivering the most precise, non-invasive treatment possible.
Many of our patients come to us after being told that surgery is their only option. They are looking for an alternative that preserves quality of life — without compromising effectiveness.
We treat international patients who expect:
- Highest medical standards
- Clear recommendations
- Fast, reliable access
All-Inclusive Treatment Program
We provide a structured, end-to-end program designed specifically for international patients.
What's Included
- Expert review of your diagnosis
- Individualized treatment planning
- CyberKnife radiosurgery (3–5 sessions)
- Follow-up and outcome monitoring
- Dedicated international patient coordination
Transparent Pricing
We provide a fixed, all-inclusive quote only after a thorough evaluation of your specific case. This ensures absolute financial clarity before you make any travel arrangements.
This program is designed for patients seeking the most advanced and least invasive option available — prioritizing long-term health over budget alternatives.
Why Patients Choose Radiosurgery Instead of Surgery
Radiosurgery is not an experimental alternative —
it is a highly precise, established treatment option for selected patients.
Sub-millimeter Precision
Targeting tumors with extreme accuracy, sparing healthy surrounding tissue.
No Incisions, No Anesthesia
A completely non-invasive procedure, eliminating surgical risks.
Completed Within Days
Typically requires only 3 to 5 short sessions, not weeks of treatment.
Minimal Interruption
Return to your daily life and routine almost immediately after treatment.
Proven Long-term Outcomes
Extensive clinical data supporting high efficacy rates.
Designed for International Patients
We understand that traveling for medical care requires clarity and efficiency. Our dedicated team ensures a seamless experience from your first inquiry to your final follow-up.
Fast scheduling
Often within days of initial contact
Clear communication
All consultations and documents in English
Travel assistance
Support with accommodation and logistics
Structured process
Time-efficient treatment timeline
Live Patient Support
"Our international desk is ready to review your case immediately."
What Our Patients Value Most
"I was looking for an alternative to surgery. The precision, the speed, and the overall experience exceeded my expectations."
International Patient
Treated in 2023
What Our Patients Value Most
"The treatment was completely pain-free and I was able to return to my normal life immediately. The team was incredibly supportive."
International Patient
Treated in 2024
What Our Patients Value Most
"The entire experience at ERCM was highly professional. The CyberKnife technology is truly remarkable and gave me peace of mind."
International Patient
Treated in 2024
Have Questions About Your Diagnosis or Treatment?
Navigating a prostate cancer diagnosis can be overwhelming. The AI Assistant of Prof. Muacevic is trained on the latest medical guidelines and our clinic's specific CyberKnife protocols to provide you with immediate, accurate answers.
- Instant answers about CyberKnife therapy and alternatives.
- Information on side effects, recovery, and success rates.
Common symptoms
Prostate cancer can vary in its symptoms and is often asymptomatic in its early stages. This means that symptoms you wouldn't typically expect to be associated with your prostate may also occur.
Bladder problems
Difficulty urinating, frequent urge to urinate, a weak urine stream.
Blood in the urine
The appearance of blood in the urine can be an alarm signal and requires urgent medical examination.
Back pain or bone pain
Advanced prostate cancer can spread to the bones and cause pain in the lower back or in the bones themselves.
Weight loss & general malaise
In advanced stages, unintentional weight loss and general malaise may occur.
Causes & risk factors
The development of prostate cancer can be influenced by various factors. Although the exact causes are not fully understood, there are some known risk factors and potential triggers.
Age
The risk of cancer increases with age: men over 50 are more frequently affected, and most cases occur after the age of 65.
Genetic predisposition
Men with a family history of prostate cancer have an increased risk, for example, if their father or brother has already been diagnosed.
Hormonal influences
Hormonal changes, particularly an increase in the male sex hormone testosterone, can promote the growth of cancer cells in the prostate.
Inflammations
Prostate infections may slightly increase the risk of cancer. Lifestyle factors, such as physical fitness, may also be associated with the development.
Diagnostic procedures
Diagnosis is usually made during routine checkups or based on specific symptoms. We briefly introduce the most important diagnostic procedures:
PSA test (prostate-specific antigen)
This blood test measures the concentration of PSA in your blood. An elevated PSA level can indicate prostate cancer, but it can also have other causes.
Digital rectal examination (DRE)
During this physical examination, the doctor palpates the prostate through the rectum to look for changes or lumps.
Imaging techniques
Magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS) provide a detailed view of the prostate to identify tumors and assess their extent.
Tissue sample (Biopsy)
If abnormalities are detected, a tissue sample should be taken from your prostate and examined to determine if cancer cells are present. The Gleason score is determined based on the tissue sample.
Staging
If prostate cancer is diagnosed, other tests may be done to determine the stage and spread, including: MRI, bone scintigraphy, or positron emission tomography (PET-CT).
Gleason Score
The Gleason score describes the extent or degree of tissue changes and is crucial for further treatment options.
Risk Assessment by Score
| Gleason Score | Histological pattern |
|---|---|
| 6 | Well differentiated (low degree) |
| 7 | Moderately differentiated, with the subgroup:
|
| 8 | Poorly differentiated |
| 9-10 | Very poorly differentiated |
What is the prognosis?
The prognosis depends primarily on individual factors, including the Gleason score, PSA level, your age, and general health. Early diagnosis and tailored treatment plans therefore play a crucial role in improving your chances of recovery.
Frequently Asked Questions
Clear answers about the CyberKnife treatment, costs, and travel arrangements.
Sabine Schatz
Your Personal Patient Coordinator
From your initial inquiry to your arrival in Munich and throughout your entire treatment, Sabine is here to ensure your journey is seamless, comfortable, and fully supported.
Get a Personal Medical Assessment
Send us your medical reports and receive a clear expert opinion within 24 hours.
Why request a review?
- • Find out if you are a candidate for CyberKnife
- • Get a clear timeline and cost estimate
- • No obligation to proceed with treatment
Secure Patient Portal
To ensure the highest level of data protection for your medical records, we process all inquiries through our secure ERCM contact portal.
Scientific Foundation
Our treatment protocols are backed by extensive clinical research and long-term studies published in leading medical journals.
Jäger, T. Früherkennung von Prostatakrebs. Forum 2024; Published 24 September 2024.
View Publicationvan As, N., Yasar, B., Griffin, C., Patel, J., Tree, A. C., Ostler, P. et al., Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial. Eur Urol 2024;86(6):566-576.
View Publicationvan As, N., Griffin, C., Baum, A., Patel, J., Ostler, P. et al., Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024;391(15):1413-1425.
View PublicationBolam, K. A., Bojsen-Møller, E., Wallin, P., Paulsson, S., Lindwall, M. et al., Association between change in cardiorespiratory fitness and prostate cancer incidence and mortality in 57 652 Swedish men. Br J Sports Med 2024;58:366-372.
View PublicationKishan, A. U., Dang, A., Katz, A. J., Mantz, C. A., Collins, S. P. et al., Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019;2(2):e188006.
View PublicationKrug, D., Imhoff, D., Haidenberger, A. et al., Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial. Strahlenther Onkol 2023;199(6):565-573.
View Publication